Moran Sean F. 4

What Happened
Sean F. Moran, Chief Financial Officer of Corbus Pharmaceuticals Holdings, sold 4,701 shares in an open-market transaction on February 13, 2026. The weighted-average sale price was $7.78, producing total proceeds of approximately $36,588. The filing lists this as a sale (S) and notes the shares were sold to satisfy tax-withholding obligations tied to RSU vesting — not as a discretionary trade.

Key Details

• Transaction date: 2026-02-13; weighted-average price: $7.78; total value: ~$36,588.
• Price range: shares were sold in multiple trades at prices between $7.58 and $7.96. The filer can provide a per-price breakdown on request.
• Reason: Sale effected under a Rule 10b5-1 trading plan adopted March 14, 2025, and mandated by the issuer’s "sell-to-cover" tax-withholding election (i.e., routine tax withholding).
• Shares owned after transaction: the filing notes that the reported ownership figure includes 68,795 unvested RSUs subject to previously reported vesting schedules. (The total post-sale beneficial ownership figure was not provided in the data supplied here.)
• Filing timing: Form 4 was filed on 2026-02-18 for a 2026-02-13 trade. Given Form 4 is normally due within two business days, this appears to have been filed late by one business day (Feb 16, 2026 was a federal holiday).

Context
This was a routine, non-discretionary "sell to cover" tied to RSU vesting and executed under a pre-established 10b5-1 plan. Such transactions are typically done to satisfy tax obligations and should not be read as an independent signal of the insider’s view on the company’s stock.